Press releaseBusiness Wire
TCGX Acquisition
TCGX · NASDAQ
$10.10+$0.07 (+0.70%)TodayMarket closed ·
Prev close $10.03
Latest news
- Press releaseBusiness Wire
TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, A Potential First-in-Class Treatment for Migraine
- Press releaseBusiness Wire
TCGX Acquisition Corp. Announces Completion of its Initial Public Offering
- Press releaseBusiness Wire
TCGX Acquisition Corp. Announces Pricing of $75,000,000 Initial Public Offering
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.